Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates

Insmed (INSM) came out with a quarterly loss of $1.94 per share versus the Zacks Consensus Estimate of a loss of$ 1.22. This compares to loss of $1.78 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -59.02%. A quarter ago, it was expected that this biopharmaceutical developing inhaled treatments for patients battling rare lung diseases would post a loss of$ 1.22 per share when it actually produced a loss of $1.06, delivering ...